Trial Profile
Safety, Tolerability and Pharmacokinetics of Multiple Rising Inhaled Doses (7.5 to 60 mg Daily for 12 Days) of BIBW 2948 BS Inhalation Powder, Hard Capsule for HandiHaler® in Healthy Male Volunteers (Randomised, Double-blind Placebo-controlled Within Dose Groups)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs BIBW 2948 BS (Primary)
- Indications Bronchitis; Chronic obstructive pulmonary disease
- Focus Adverse reactions
- Sponsors Boehringer Ingelheim
- 20 Aug 2014 New trial record